6 reports

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Allergy
  • Cardiovascular Disease
  • Health Services
  • Therapy
  • Company

THE DRUG CANDIDATE TARGET THE ALLERGENS (DERP ##) THAT CAN TRIGGER ALLERGIES AND ASTHMA ATTACKS DIRECTLY.

  • Allergy
  • Antifungal
  • Cardiovascular Disease
  • Health Services
  • Company

THE DRUG CANDIDATE IS A ## MER PEPTIDE ACTS BY TARGETING PROGRAMMED CELL DEATH ## LIGAND ## (PD-L##).

  • Allergy
  • Cardiovascular Disease
  • Cell Therapy
  • Health Services
  • Company

Two out of the six were considered possibly related to study drug: one in Group ## and one in Group ##.

  • Allergy
  • Antifungal
  • Cardiovascular Disease
  • Health Services
  • Company

THE DRUG CANDIDATE IS IN PHASE II STAGE FOR PEANUT ALLERGY IN ADULTS AND PEDIATRICS, GRASS POLLEN ALLERGY AND DERMATITIS GLOBALLY.

  • Allergy
  • Antifungal
  • Cardiovascular Disease
  • Health Services
  • Company

(allergy and autoimmune diagnostics) which was sold to Thermo Fisher Scientific (TMO) in September of 2011.

  • Allergy
  • Cardiovascular Disease
  • Health Services
  • Therapy
  • Company